Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
Frontiers in immunology
; 13, 2022.
Article
in English
| EuropePMC | ID: covidwho-1762664
ABSTRACT
The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine effectiveness. Here, neutralizing antibody titers elicited by mRNA-based and adenoviral vector-based vaccines against variant pseudotyped viruses were measured. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals had less neutralizing titer (IC50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest a potential benefit by second immunization following Ad26.COV2.S to increase protection from current and future variants.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Topics:
Vaccines
/
Variants
Language:
English
Journal:
Frontiers in immunology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS